Mar­tin Shkre­li will have to find a new nick­name.

A fed­er­al judge banned the for­mer biotech CEO and “Phar­ma Bro” from the drug in­dus­try on Fri­day, or­der­ing him to pay near­ly $65 mil­lion in il­lic­it prof­its. Shkre­li was con­vict­ed of se­cu­ri­ties fraud in 2017 and is cur­rent­ly serv­ing a sev­en-year prison sen­tence, though he orig­i­nal­ly gained no­to­ri­ety for rais­ing the price of the an­tipar­a­sitic drug Dara­prim from $13.50 to $750 in 2015.

“The risk of a re­cur­rence here is re­al,” Judge Denise Cote wrote in a 135-page opin­ion. “Shkre­li has not ex­pressed re­morse or any aware­ness that his ac­tions vi­o­lat­ed the law. While he takes full re­spon­si­bil­i­ty in his di­rect tes­ti­mo­ny for the in­crease of Dara­prim’s price from $17.50 to $750 per pill, he de­nies re­spon­si­bil­i­ty for vir­tu­al­ly any­thing else.”

New York at­tor­ney gen­er­al Leti­tia James al­so chimed in, say­ing in a state­ment that “Amer­i­cans can rest easy be­cause Mar­tin Shkre­li is a phar­ma bro no more.”

The FTC and sev­en states — Cal­i­for­nia, New York, Illi­nois, North Car­oli­na, Ohio, Penn­syl­va­nia and Vir­ginia — brought the suit against Shkre­li in 2020, es­sen­tial­ly claim­ing he was run­ning a drug mo­nop­oly from prison. Shkre­li, reg­u­la­tors and states said, at­tempt­ed to pre­vent Dara­prim gener­ics from reach­ing the mar­ket by block­ing com­peti­tors’ ac­cess to a key in­gre­di­ent.

De­tails of the saga con­tin­ued trick­ling out in the two years since. Hav­ing pre­vi­ous­ly brought at­ten­tion to him­self through his prison blogs and use of a con­tra­band cell phone, Shkre­li be­gan ac­tive­ly en­gag­ing in the an­ti­com­pet­i­tive scheme us­ing the prison’s com­mu­ni­ca­tions sys­tems, which were record­ed and mon­i­tored.

Op­pos­ing lawyers pounced, us­ing the calls against him in their ar­gu­ments — claim­ing at­tor­ney-client priv­i­lege did not ap­ply here — and push­ing for the life­time ban. Shkre­li’s lawyers, mean­while, as­sert­ed his sta­tus as a first-time of­fend­er meant he like­ly wouldn’t re­peat his il­lic­it ac­tiv­i­ties and sought a more le­nient 10-year in­dus­try re­stric­tion.

Ul­ti­mate­ly, the judge found Shkre­li’s ac­tions vi­o­lat­ed fed­er­al and state laws that pro­hib­it an­ti­com­pet­i­tive con­duct. Dara­prim gener­ics were de­layed mar­ket en­try by at least 18 months, Cote wrote, with Vy­era prof­it­ing $64.6 mil­lion from the scheme.

Fri­day’s rul­ing comes on the heels of an­oth­er court de­ci­sion against Shkre­li last month, in which Vy­era and its par­ent com­pa­ny, Phoenixus AG, were or­dered to pay more than $40 mil­lion for block­ing gener­ic Dara­prim ac­cess. Vy­era was re­quired to make Dara­prim avail­able to any po­ten­tial gener­ic com­peti­tor at list price and to pro­vide pri­or no­ti­fi­ca­tion of any planned phar­ma­ceu­ti­cal trans­ac­tion val­ued at $25 mil­lion or more.

Dara­prim had been the on­ly FDA-ap­proved drug to treat a po­ten­tial­ly life-threat­en­ing con­di­tion known as tox­o­plas­mo­sis. Im­muno­com­pro­mised in­di­vid­u­als and those with HIV are par­tic­u­lar­ly vul­ner­a­ble to the par­a­sitic dis­ease. Shkre­li’s 2015 move to spike the price by more than 4,000% be­came a flash­point in grow­ing crit­i­cism against in­dus­try-wide price-goug­ing.

We now know where Roche’s ex-pharma chief Bill Anderson is going.

German pharma giant Bayer announced Wednesday that Anderson will be taking on the role as CEO, less than six weeks after Anderson stepped down from his perch at Roche as head of the group’s pharmaceutical division.

Roche announced back in December that Anderson would depart on Dec. 31 to “pursue opportunities outside of Roche.” His replacement, Genentech vet and Roche’s current head of global product strategy, Teresa Graham, will start her role in March.

President Joe Biden made clear in his “finish the job” State of the Union address last night that one of those jobs to be finished is insulin prices.

Biden’s push again to tackle insulin prices, after Republicans rebuffed the idea last summer and just after Biden won Medicare drug price negotiations/caps via the Inflation Reduction Act, shows how heavily he’s leaning into this work.

Six weeks into his new role at the helm of Teva Pharmaceutical, Richard Francis said it’s time to “get back to growth,” starting with a good look at the company’s priorities.

The chief executive has kicked off a strategic review, he announced during Teva’s quarterly call, which will continue over the next several months and produce results sometime in the middle of 2023. That means some pipeline cuts may be in store, he told Endpoints News, while declining to offer much more detail.

As talk of AI this-and-that gobbles up headline after headline, one Big Pharma is losing its AI leader as she transitions to another drug giant: Iya Khalil will trade in her hat as Novartis’ go-to expert and leader in the space for Merck as VP and head of data, AI and genome sciences next week.

After nearly three years leading the artificial intelligence team at Novartis — as Big Pharma and biotechs alike latch onto the ripening AI-for-drug-discovery mode of operation — Khalil will switch employers to head up a similar post at Merck, where she’ll work out of Cambridge, MA beginning Feb. 13, the company tells Endpoints News.